Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Cacicol 20
- Development stage
- Phase 3
- Lead developer
- Théa Pharmaceuticals
- Modality
- Biodegradable Polymers → Polymer-based Nanoparticles → Nanoparticles → Drug Delivery Systems, Non-biodegradable Polymers → Polymer-based Nanoparticles → Nanoparticles → Drug Delivery Systems, Injectable Hydrogels → Hydrogel Systems → Drug Delivery Systems, Implantable Hydrogels → Hydrogel Systems → Drug Delivery Systems
- Administration
- Ophthalmic
01
Overview
Cacicol 20 is a topical ophthalmic regenerative agent classified as the first ReGeneraTing Agent (RGTA) for ophthalmic use. Its active component is poly(carboxymethylglucose sulfate), a biopolymer that mimics the structure and function of heparan sulfate glycosaminoglycans (HS GAGs), which are natural constituents of the extracellular matrix. By mimicking HS, Cacicol 20 helps restore and protect the extracellular matrix, promoting cellular communication, cellular homeostasis, and tissue repair. It is indicated for the treatment of corneal dystrophies, chronic corneal ulcers, neurotrophic corneal ulcers, and to accelerate corneal wound healing and nerve regeneration following surgical procedures like phototherapeutic keratectomy or corneal cross-linking[1][3][5][7].
- Brand names
- CacicolCacicol 20Cacicol20Cacicol-20
- Other names
- Poly(carboxymethylglucose sulfate)regenerating agentRGTA
02
Targets
MMP12 (Macrophage Metalloelastase)
Beyond the preview
Go deeper on Cacicol 20.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Cacicol 20.